Sendero Wealth Management’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.49M Buy
26,039
+2,132
+9% +$395K 0.5% 38
2025
Q4
$4.77M Buy
23,907
+44
+0.2% +$7.98K 0.53% 40
2025
Q3
$3.73M Buy
23,863
+534
+2% +$84.8K 0.44% 50
2025
Q2
$3.54M Buy
+23,329
New +$3.11M 0.44% 47

Other funds holding CRL

Sendero Wealth Management's CRL Position: Q1 2026 in Review

Sendero Wealth Management increased its Charles River Laboratories (CRL) stake by 8.9% in Q1 2026, buying an estimated $395K and bringing the position to 26,039 shares worth $4.49M. The position accounts for 0.5% of the portfolio, ranked #38.

Sendero Wealth Management first reported a position in CRL in Q2 2025 and has held it in 4 quarters since. The position peaked at $4.77M in Q4 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Sendero Wealth Management held 26,039 shares of Charles River Laboratories worth $4.49M as of Q1 2026.
  • Sendero Wealth Management bought 2,132 Charles River Laboratories shares in Q1 2026, an estimated $395K.
  • Charles River Laboratories made up 0.5% of Sendero Wealth Management's portfolio in Q1 2026, its #38 holding.
  • Sendero Wealth Management first reported a position in Charles River Laboratories in Q2 2025 and has held it in 4 quarters since.
  • Sendero Wealth Management's Charles River Laboratories position peaked at $4.77M in Q4 2025.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Sendero Wealth Management's 13F filing for Q1 2026, filed 22 Apr 2026.